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Plasma inﬂammatory markers have been shown to be predictors for cardiovascular risk, however, there is no study where the levels
of plasma circulatory markers have been evaluated in coronary artery disease patients (CAD pts) positive for C. pneumoniae IgA
and high sensitive C-reactive protein (hsCRP) which may help in better understanding of disease pathogenesis. A total of 192
patients and 192 controls attending the Cardiology Outpatient Department of Safdarjung Hospital were enrolled. The levels of
plasma circulatory inﬂammatory markers were evaluated by ELISA. The levels of circulatory plasma markers (IL-4, IL-8, IL-13,
ICAM-1,andVCAM-1)weresigniﬁcantlyhigher,whereas,levelsofIL-10andIFN-γ weresigniﬁcantlylowerinCADptscompared
to healthy controls. The levels of IL-4, IL-8, and ICAM-1 (P = .007, .015, and .048) were signiﬁcantly higher, however, IL-10 and
IFN-γ were signiﬁcantly lower (P<. 001, <. 001) in C. pneumoniae IgA positive CAD pts. The levels of IL-4, IL-8, IL-13, ICAM-1,
and VCAM-1 were higher but not signiﬁcant and levels of IL-10 and IFN-γ were signiﬁcantly (P<. 001, <. 001) lower in hsCRP
positive CAD pts. Our study suggested that circulatory cytokines, namely, IL-4, IL-8, and adhesive molecules like ICAM-1 were
enhanced after infection with C. pneumoniae whereas in contrast to this IL-10 and IFN-λ were lowered. Suggesting the important
role of these cytokines in progression of CAD.
Copyright © 2009 Hem Chandra Jha et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Atherosclerosis is an inﬂammatory disease which may be the
outcome of responses to microbial antigens [1, 2]. Several
conserved components of the bacterial cell wall have been
shown to bind to receptors on the cell surface of monocyte
and macrophages which may induce production of proin-
ﬂammatory cytokines [3]. The role of chronic low-grade
infection of the arterial wall with Chlamydia pneumoniae
(C. pneumoniae) in the pathogenesis of atherosclerosis has
been suggested in a series of epidemiological and patho-
logical studies and may induce innate immunity, molecular
mimicry, and autoimmunity as well as direct infection of
tissues [4–8]. Earlier prospective studies have shown CRP to
be a strong independent predictor of coronary events [1].
It seems that the macrophages deactivating cytokines IL-4
and IL-13 display proinﬂammatory activities in the vascular
system [9] and that IL-8 may have a role as a leukocyte
chemoattractant during atherogenesis [10]. Intercellular
adhesion molecule-1 (ICAM-1), a major adhesion receptor
expressed on the endothelium, is involved in monocyte
adhesion to endothelial cells [11]. The vascular adhesion
molecule (VCAM-1) has been reported to bind particularly
to those classes of leukocytes found in nascent atheroma
consistingofthemonocyteandtheTlymphocyte[12].Thus,
proinﬂammatory cytokines may link hypercholesterolemia
to VCAM-1 expression [13]. We reported earlier association
of hsCRP and IL-6 with C. pneumoniae IgA serology in
CAD patients [14, 15], however, there is no study where
levels of these plasma circulatory markers in C. pneumoniae2 Mediators of Inﬂammation
IgA positive and hsCRP positive groups of CAD patients
have been evaluated which is required for understanding
pathogenesis of CAD. Hence the aim of this study was
to perceive the levels of plasma circulatory inﬂammatory
markers in CAD patients in the presence of well established
CAD markers, namely, C. pneumoniae IgA and hsCRP in
Indian population.
2.MaterialsandMethods
2.1. Patients. A total of 192 patients (148 males and 44
females) attending the Cardiology Outpatient Department
of Safdarjung hospital from March 2005 to June 2007 for
angiographically conﬁrmed CAD were enrolled for the study
after prior written consent. In addition, 192 age and sex
matched healthy controls with no evidence of CAD (142
males and 50 females) were also included in the study.
The study received clearance from the hospital ethics review
committee.
2.2.InclusionCriteria. EvidenceofCADrequiredatleastone
of the following: (1) signiﬁcant stenosis (70% of luminal
diameter) in at least one major coronary artery proved by
angiography and had undertaken either percutaneous coro-
nary intervention or coronary artery bypass graft (CABG);
(2) positive stress myocardial perfusion imaging studies for
ischemia.
2.3. Exclusion Criteria. Patients were not included if any of
the following was present myocardial infarction or CABG in
the preceding 3 months, unstable angina, signiﬁcant valvular
heart disease, blood pressure 180/100mm.
2.4. Collection of Samples. Venous blood (5mL) was col-
lected in nonheparinized tubes from CAD patients and
controls. Serum was separated within 2 hours of blood
collection and kept at −80◦C until used for detection of
hsCRP, IL-4, IL-8, IL-10, IL-13, IFN-λ , ICAM-1 and VCAM-
1, and antibodies against C. pneumoniae IgA.
2.5. Serology and Antibody Level of Atherosclerotic Marker.
Detection of antibodies for C. pneumoniae speciﬁc IgA
was performed using commercially available ELISA kit (R-
Biopharm AG, Germany), as mentioned earlier [8]. For
detection of antibodies to hsCRP, ELISA was performed
using kits (Calibiotech Inc., Calif, USA) as per manufac-
turer’s instructions and level of the hsCRP (>3mg/L) in
serum was considered as hsCRP positive in dichotomized
result. Detection of concentration of interleukins (IL-4, IL-
8, IL-10, IL-13, and IFN-λ ), adhesive molecules (ICAM-1
and VCAM-1) was performed using commercially available
ELISA kit (e-biosciences, San Diego, Calif, USA) and (Dia-
clone, France) as, respectively, manufacturer’s instructions.
Sensitivity and speciﬁcity for all kits used in the study were
>95%.
2.6. Statistical Analysis. Diﬀerences between two groups
were evaluated using Mann-Whitney U-test. For compar-
ing binary related characteristics χ-square test, ﬁsher-exact
statistic was used. Simultaneously, an alpha level of 0.05 was
set as the level of signiﬁcance.
3. Results
3.1. Classiﬁcation of CAD Patients and Controls on the Basis of
Age and Sex. Three age groups of CAD patients and controls
were included in this study, however, none of the groups
were found to be signiﬁcantly diﬀerent. Males and females
were also not found to be signiﬁcantly diﬀerent when CAD
patients and controls were compared (Table 1).
3.2. Evaluation of Plasma Circulatory Markers in CAD pts and
Controls. Levels of plasma circulatory markers viz IL-4, IL-8,
IL-13, ICAM-1 and VCAM-1 were signiﬁcantly higher (P<
.001, <.001, .004, <.001, <.001) in contrast to, levels of IL-10
and IFN-λ which were signiﬁcantly lower (P<. 001) in CAD
pts as compared to controls (Table 2).
3.3. Evaluation of Plasma Circulatory Markers in C. pneumo-
niae IgA Positive CAD pts and Controls. Mean levels of IL-4,
IL-8, and ICAM-1 were signiﬁcantly higher (P = .007, .015,
<.001, <.001, and .048) in C. pneumoniae IgA positive CAD
pts as compared to C. pneumoniae IgA negative CAD pts,
whereasthelevelsofIL-10andIFN-λweresigniﬁcantlylower
(P<. 001, <.001). Mean levels of IL-4 were signiﬁcantly
higher (P<. 001) and IFN-λ was signiﬁcantly lower (P =
.006) in C. pneumoniae IgA positive controls as compared to
C. pneumoniae I g An e g a t i v ec o n t r o l s( Table 3).
3.4. Evaluation of Plasma Circulatory Markers in hsCRP
Positive CAD pts and Controls. Mean levels of plasma
circulatory markers IL-4, IL-8, IL-13, ICAM-1, and VCAM-1
were higher but not signiﬁcant while levels of IL-10 and IFN-
λ were signiﬁcantly lower (P<. 001) in hsCRP positive CAD
pts as compared to hsCRP negative CAD pts. Additionally,
similar results were found in hsCRP positive controls as
compared to hsCRP negative controls (Table 4).
4. Discussion
A variety of plasma inﬂammatory markers have been shown
to predict future cardiovascular risk [16] and is useful for
risk stratiﬁcation and also for identifying those patients
who may beneﬁt from targeted interventional therapy. It has
been reported that C. pneumoniae induces much more IL-
6 and IL-8 and lower levels of IFN-γ compared to other
Gram-positive bacteria [3, 17]. The induction of monocyte
procoagulant activity with either IL-6 or IL-8 has been
proposed as a possible link between inﬂammation and
thrombosis in patients with CAD [18]. IL-8 has also been
reportedtoplayaminorroleinmediatingmonocyterecruit-
ment and adhesion associated with neutrophil chemotaxis
[19]. Increased expression of cell adhesion molecules in
response to infection with C. pneumoniae has also beenMediators of Inﬂammation 3
Table 1: Characteristics of coronary artery disease patients and controls.
Characteristics Age groups Patients (n = 192) Control (n = 192) P-value
Age (years)
35–49 67 (34.89) 78 (40.62) .292
50–64 93 (48.43) 85 (44.27) .474
65–79 32 (16.66) 29 (15.10) .780
Sex Male 148 (77.08) 142 (73.95) .553
Female 44 (22.91) 50 (26.04) .553
Figure in parenthesis indicates % positivity.
Table 2: Evaluation of plasma circulatory markers in coronary artery disease patients and controls.
Plasma circulatory markers CAD patients (n = 192) Controls (n = 192) P-value
mean ± SD mean ± SD
IL-4 (pg/mL) 1.29 ±0.17 0.97 ±0.12 <.001∗
IL-8 (pg/mL) 3.27 ±0.31 2.36 ±0.22 <.001∗
IL-10 (pg/mL) 1.83 ±0.16 1.95 ±0.19 <.001∗
IL-13 (pg/mL) 4.81 ±0.28 4.25 ±0.27 .004∗
IFN-λ (pg/mL) 1.58 ±0.14 1.55 ±0.16 <.001∗
ICAM-1 (ng/mL) 14.38 ±1.16 13.12 ±1.11 <.001∗
VCAM-1 (ng/mL) 73.91 ±6.71 54.24 ±4.84 <.001∗
CAD: coronary artery disease; ∗: signiﬁcant; SD: standard deviation; IL: interleukin; ng: nanogram; pg: pikogram; mL: mililiter; IFN: interferon; ICAM:
intercellular adhesion molecule; VCAM: vascular adhesion molecule.






P-value IgA (+ve) (n = 155) IgA (−ve) (n = 37) IgA (+ve) (n = 77) IgA (−ve) (n = 115)
mean ± SD mean ± SD mean ± SD mean ± SD
IL-4 (pg/mL) 1.31 ±0.13 1.17 ±0.12 .007∗ 1.06 ±0.08 0.92 ±0.08 <.001∗
IL-8 (pg/mL) 3.41 ±0.31 2.76 ±0.26 .015∗ 2.46 ±0.23 2.31 ±0.21 .444
IL-10 (pg/mL) 1.82 ±0.11 1.86 ±0.11 <.001∗ 1.95 ±0.14 1.96 ±0.15 .879
IL-13 (pg/mL) 4.84 ±0.41 4.70 ±0.42 .918 4.34 ±0.36 4.20 ±0.40 .773
IFN-λ (pg/mL) 1.57 ±0.14 1.65 ±0.12 <.001∗ 1.54 ±0.14 1.56 ±0.13 .006∗
ICAM-1 (ng/mL) 14.54 ±1.21 13.75 ±1.24 .048∗ 13.16 ±1.10 13.10 ± 1.09 .528
VCAM-1 (ng/mL) 74.33 ±6.27 72.21 ±6.15 .454 54.39 ±4.76 54.10 ± 4.39 .564
CAD: coronary artery disease; ∗: signiﬁcant; SD: standard deviation; IL: interleukin; ng: nanogram; pg: pikogram; mL: mililiter; IFN: interferon; ICAM:
Intercellular adhesion molecule; VCAM: vascular adhesion molecule; IgA: immunoglobulin A; +ve: positive; −ve: negative.






P-value hsCRP (+ve) (n = 116) hsCRP (−ve) (n = 76) hsCRP (+ve) (n = 60) hsCRP (−ve) (n = 132)
mean ± SD mean ± SD mean ± SD mean ± SD
IL-4 (pg/mL) 1.31 ±0.12 1.26 ±0.11 .719 1.00 ±0.13 0.96 ±0.12 .090
IL-8 (pg/mL) 3.32 ±0.31 3.20 ±0.26 .573 2.53 ±0.21 2.29 ±0.18 .207
IL-10 (pg/mL) 1.82 ±0.13 1.85 ±0.14 <.001∗ 1.94 ±0.15 1.96 ±0.24 <.001∗
IL-13 (pg/mL) 4.86 ±0.30 4.74 ±0.31 .118 4.30 ±0.33 4.23 ±0.30 .668
IFN-λ (pg/mL) 1.57 ±0.12 1.59 ±0.13 <.001∗ 1.54 ±0.19 1.56 ±0.17 <.001∗
ICAM-1 (ng/mL) 14.53 ±1.07 14.16 ±1.17 .563 13.25 ±1.13 13.06 ±1.09 .330
VCAM-1 (ng/mL) 74.20 ±7.21 73.47 ±6.91 .658 54.60 ±4.92 54.10 ±4.39 .874
CAD: coronary artery disease; ∗: signiﬁcant; SD: standard deviation; IL: interleukin; ng: nanogram; pg: pikogram; mL: mililiter; IFN: interferon; ICAM:
intercellular adhesion molecule; VCAM: vascular adhesion molecule; hsCRP: high-sensitive C-reactive protein; +ve: positive; −ve: negative.4 Mediators of Inﬂammation
reported [20, 21]. In our study levels of cytokines IL-4, IL-
8, and ICAM-1 were detected higher and levels of IL-10
and IFN-λ were lower in C. pneumoniae positive compared
to C. pneumoniae negative CAD patients. Moreover, levels
of IL-4, IL-8, IL-13, ICAM-1, and VCAM-1 were detected
higher but not signiﬁcant in hsCRP positive CAD pts
compared to hsCRP negative CAD patients. It has been
earlier reported that CRP clearly enhances IL-8 production
at 8 to 24 hours of incubation, although a considerably
less potent than CRP [22, 23]. However, Gabay et al.
showed that IL-4 and IL-13 decreased the levels of CRP
in primary hepatocytes and hepatoma hepG2 cells [24].
Kieda et al. reported that leukocyte recruitment to the
endothelium is mediated by the interaction of adhesion
molecule receptors expressed on the surface of endothelium
cells for eﬀective host defense against bacteria [25]. Also
it is reported that very late antigen-4 (VLA-4), a major
adhesion receptor is expressed by T lymphocytes, mediates
T-cell adhesion in the microvasculature via an interaction
with VCAM-1 on activated endothelial cells [26]. Kawanami
et al. showed that CRP induces VCAM-1 gene expression
through NF-κB activation in vascular endothelial cells [27],
which is parallel to our ﬁndings where elevated hsCRP was
detected in serum of CAD patients. In our study among
diﬀerent age groups, levels of C. pneumoniae IgA were not
signiﬁcantly diﬀerent (data not shown). Similar results were
reported by Masato et al. whereas it is contradictory to
that reported by Hahn et al. [28] and Nishimura et al.
[29].
5. Conclusion
Overall, our study suggested that circulatory cytokines,
namely, IL-4, IL-8 and adhesive molecules like ICAM-1 were
enhanced in CAD patients infected with C. pneumoniae
whereas in contrast to this IL-10 and IFN-λ were lowered.
Additionally, these cytokines were also enhanced in hsCRP
positive CAD-pts, suggesting the important role of these
cytokines in progression of CAD.
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